Arcturus Therapeutics Holdings Inc. has entered a strategic collaboration with Thermo Fisher Scientific Inc. to support the Phase 3 development and potential commercialization of ARCT-032, its investigational mRNA therapy for cystic fibrosis. The partnership aims to leverage Thermo Fisher's global infrastructure and CDMO capabilities to accelerate the program through clinical stages and into commercial supply. This collaboration is intended to streamline the development process for the rare disease therapeutic.

Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services utilizing its Accelerator Drug Development solutions. If Phase 2 yields positive results, Arcturus expects to conduct its Phase 3 program through Thermo Fisher's PPD clinical research business. The collaboration integrates manufacturing, clinical research, and commercial readiness services to reduce operational complexity.

Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing rights under a separate commercial agreement. This structure aligns with Arcturus's goal of efficiently advancing its cystic fibrosis program while preparing for potential commercial supply. The agreement combines Thermo Fisher's manufacturing and clinical research capabilities to support the therapy from Phase 3 through potential commercialization.

Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics, highlighted the strategic value of the partnership, citing Thermo Fisher's proven ability to support complex mRNA programs. Mike Shafer, Executive Vice President and President of Biopharma Services at Thermo Fisher Scientific, emphasized the value of the integrated model in helping customers simplify development and accelerate the delivery of innovative therapies to patients.

Key Collaboration Details

Freedom Broker analyst Ilya Zubkov has initiated coverage on Arcturus Therapeutics with a Buy rating and announced a price target of $27. This rating suggests a positive outlook for the company's stock performance.

Coverage Details

The initiation of coverage provides a new investment perspective on Arcturus Therapeutics. The price target set by the analyst indicates the expected valuation level for the shares.